LOS ANGELES, CA / ACCESSWIRE / May 29, 2019 / CB2 Insights (CSE: CBII; OTCQB: CBIIF) ("CB2" or the "Company"), a leading data-analytics company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that CEO Prad Sekar will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 2:20PM PST / 5:20PM EST. Mr. Sekar is also scheduled to meet with investors throughout the day on June 4.
"CB2 Insights has had several transformational catalysts since attending our first LD Micro event in December 2018," said Mr. Sekar. "First, we closed a $5.74 million oversubscribed private placement financing, which we conducted concurrently with our go-public event. Second, we began our consolidation strategy to expand our clinical data pool by acquiring MedEval Clinic LLC , a medical cannabis clinic group in Colorado and Arizona, as well as the assets of Colorado-based medical cannabis clinic group Rae of Sunshine Health Services LLC. We also initiated integration with Premier Health Group, a leading Electronic Medical Records ("EMR") platform, giving more than 4,600 physicians and healthcare practitioners using Premier Health's Juno EMR platform access to the industry's only medical cannabis-specific Clinical Decision Support tool. We look forward to updating shareholders on our progress as well as introducing CB2 Insights' story to new potential investors."
"This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President of LD Micro. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever growing community."
The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.
View CB2 Insights' profile here: https://www.ldmicro.com/profile/CBII.CN.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.
For more information please visit www.cb2insights.com.
Chief Marketing Officer
For Investor Inquiries:
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2's filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.
Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.
No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.
SOURCE: CB2 Insights